Groundbreaking research of ElleVet’s proprietary CBD + CBDA formulation addresses critical gap in feline mobility support.
SOUTH PORTLAND, MAINE (December 2, 2025) – ElleVet Sciences, the leader in science-driven CBD + CBDA products for pets, is proud to announce the publication of a groundbreaking feline mobility study demonstrating the safety and efficacy of its proprietary CBD + CBDA formulation for cats experiencing mobility challenges. Building on the company’s longstanding commitment to science-driven pet health solutions, this milestone marks a significant step in addressing critical gaps in feline mobility care, with the goal of helping cats move more comfortably, play more, and enjoy a better quality of life.
This research, published in The Journal of Feline Medicine and Surgery, underscores ElleVet’s commitment to offering veterinarians and pet parents a much-needed solution for supporting mobility in cats, a historically underserved population. Adding to over 20 published clinical studies and trials at leading veterinary research institutions, ElleVet remains the first and only organization to conduct successful clinical trials on CBD + CBDA for pets.
“An overwhelming number of cats experience mobility challenges, but there are very limited safe and effective long-term options to help,” said Joseph Wakshlag, DVM, PhD, DACVIM (Nutrition), DACVSMR and Chief Veterinary Medical Officer of ElleVet. “Our goal with this research – and its application in ElleVet’s feline products – is to fill a significant void in feline care; the improvement reported from vets and cat owners in this study validates our efforts.”
The study evaluated a six-week course of cannabidiol (CBD)/cannabidiolic acid (CBDA)-rich hemp paste in cats experiencing mobility challenges. It was a randomized, double-blinded, placebo-controlled crossover design, where each cat received both the paste and the placebo in sequence.
In the cats who completed the study, key findings include:
- Over 70% of cats experienced noticeable improvements, reported by both veterinarians and owners.
- Specific measures of mobility, including gait, navigating stairs, jumping up and down, and play behavior, were all improved during the study in the cats who received CBD/CBDA.
- Bloodwork showed no significant safety concerns between groups after six weeks of use.
- To view the full study, copy and paste this link into your browser: https://journals.sagepub.com/doi/full/10.1177/1098612X251367629
“Using our science-first approach to understand and address the unique needs of cats has long been a driving force behind our work at ElleVet,” said Haley Israelson, CEO of ElleVet Sciences. “We’re thrilled to publish this research and highlight our impact in expanding mobility support options for cats, and ultimately, improving quality of life – both for cats and the people who love them.”
Through their research-led approach to product development and understanding of the nuances of feline behavior, ElleVet remains uniquely positioned to advance innovation in cat health and well-being. For more information about ElleVet’s clinical studies and research, visit www.ellevetsciences.com/cbd-science.
About ElleVet Sciences: ElleVet Sciences is a leading science-driven animal health company headquartered in South Portland, Maine. As the first and only organization to conduct successful clinical trials on the safety and efficacy of CBD + CBDA for pets, ElleVet continues to lead the field through research and innovation in collaboration with top veterinary professionals and institutions. The company has pioneered and patented safe, effective products for dogs, cats, and horses, offering support for mobility, stress, canine skin health, and canine brain function. Carried by thousands of veterinary clinics across the US, ElleVet is committed to improving the lives of companion animals, with both heart and science at the core of its mission.
Media Contact:
###